ecancermedicalscience

Research

Phase 2 non-randomised trial of secondary cytoreduction and hyperthermic intraperitoneal chemotherapy in recurrent platinum-sensitive ovarian cancer

5 Jul 2021
Hemanth Raj, Marri Sri Santosh Keerthi, Ravisankar Palaniappan, Ujwala Prakash, Manikandan Dhanushkodi, Trivadi S Ganesan

Background: The role of secondary cytoreduction with hyperthermic intraperitoneal chemotherapy (HIPEC) is not clearly defined in recurrent platinum-sensitive ovarian cancer (PSOC). There is a paucity of studies on secondary cytoreduction with HIPEC in PSOC from developing countries like India. This study was done to assess the feasibility and safety of secondary cytoreduction and HIPEC in recurrent PSOC.

Methods: This was a prospective, non-randomised, open-label, phase 2 trial of secondary cytoreduction and HIPEC (Cisplatin 75 mg/m2 43°C over 60 minutes) in patients with recurrent platinum-sensitive epithelial carcinoma of ovary/fallopian tube/peritoneum done in a tertiary cancer centre from February 2016 to August 2019. The primary outcome was to assess the overall survival (OS) and the secondary outcomes were to assess the progression-free survival (PFS) and toxicity.

Results: Twenty-seven patients were screened and among them, 15 patients were included in this analysis with a median follow-up of 25 months. The mean cancer antigen (CA) 125 at the time of recurrence was 149 U/mL (range: 10–2,030 U/mL) and the median platinum-free interval was 21 months. The perioperative chemotherapy used was paclitaxel + carboplatin 53.3% (8/15), liposomal doxorubicin + carboplatin 40% (6/15) and none 6.5% (1/15). The median Peritoneal Carcinomatosis Index score was 8 (range: 3–25). The Clavien Dindo score was I, II and III in 6.7%, 26.7% and 13.3% patients, respectively. Recurrence was radiological and biochemical in 60% (9/15) and 7% (1/15), respectively. The most common site of recurrence was intra-abdominal (peritoneal). The median PFS and OS were 15 months (range: 0–34) and 26 months (range: 23–29), respectively. The grade 3 or 4 toxicity was 40%.

Conclusion: Secondary cytoreduction with HIPEC is feasible and safe in recurrent PSOC. Conclusive evidence that secondary cytoreduction with HIPEC is essential awaits the results from ongoing randomised controlled trials.

Related Articles

Mariana Carvalho Gouveia, Cassio Murilo Hidalgo Filho, Raquel Andrade Moreno, Heitor Castelo Branco Rodrigues Alves, Aline Sgnolf Ayres, Laura Testa, Renata Colombo Bonadio
Ralph Victor Yap, Deanne Lou Marquez, Frances Marion De La Serna
Vachaspati Kumar Mishra, Ajeet Kumar Gandhi, Madhup Rastogi, Rakhi Verma, Rohini Khurana, Rahat Hadi, Vikas Sharma, Akash Agarwal, Anoop Kumar Srivastava
Sattam A Halaseh, Amro Al-Karadsheh, Deborah Mukherji, Abdelrahman Alhjahaja, Ala’a Farkouh, Akram Al-Ibraheem, Ibrahim Abu Gheida, Sultan Al-Khateeb, Humaid Al-Shamsi, Mohammed Shahait
Samson Chisele, Mulindi Mwanahamuntu, Paul Kamfwa, Mukatimui Kalima-Munalula, Swali Fundafunda, Kenneth Chanda, Maya M Hicks, Leeya F Pinder, Krista S Pfaendler, Groesbeck P Parham, Michael L Hicks